360 Merrimack Street
9 articles with Nexcelom Bioscience
Ampersand Capital Partners announced that it has completed the sale of Nexcelom Bioscience, one of its portfolio companies and a leading provider of automated cell counting solutions, to PerkinElmer for $260 million in cash.
PerkinElmer expands its presence with the acquisition of Nexcelom, which would allow the company to expand global efforts to accelerate time to target and time to market for novel therapeutics.
Nexcelom Supports Biotech Startups with a Donation of Five Cellometer Auto 2000, an Automated Cell Viability Counter, to LabCentral
The rise of immune-oncology and adoptive cell therapy is driving the boom of several biotech startup organizations that use the types of protocols and methods developed on Cellometer instruments by Nexcelom.
The Cellaca™ MX utilizes Nexcelom's innovative cellular analysis technology for accurate cell sample concentration, viability and morphology measurements.
Nexcelom Bioscience, a leading provider of cell counting and analysis products for biomedical research and the biopharma industry, announced today that it has received a strategic investment from Ampersand Capital Partners.
Nexcelom Bioscience to Distribute FCS Express 4 Cytometry Software with Cellometer Vision CBA Instruments
Nexcelom Bioscience Adds User-Changeable Fluorescence Optics Modules to Cellometer Vision, Its Automated Fluorescence-Based Imaging Cell Counter and Analyzer
Nexcelom Bioscience Expands Automated Cell Counting Product Offerings with Launch of Cellometer(R) Auto X4
Nexcelom Bioscience Extends Automated Cell Counting Product Platform with Launch of Cellometer(R) Auto M10(TM)